Cameron Reynolds: Yes, absolutely. So obviously, it was very good preliminary data, and we’ve had a lot of interest from partners, which we’re very excited about, and it is bigger than us. So we’re very excited. But of course, we’re working all the time not only on more data, which is obviously very important in a range of cancers which we aim to be presenting at specific conferences for those cancers as well as we’re working on the — it has not been optimized at all. So we’re going through all the things to optimize it to make it as simple and easy as routine as possible. And also the optimizations should also help with the overall accuracy. So overall, I think, as you know, Bruce, I’m a very optimistic person, but I’m very happy and a little surprised how quickly it’s actually gone even since ESMO with the level of interest and Jake at the conference next week, the [Indiscernible] conference also in Madrid.
So we’re talking to a lot of our other potential partners there. So expect to see a lot of information through this year and into next year and data as we said in Q1.
Bruce Jackson: Alright, great. Thank you for taking my question.
Operator: Our next question comes from Tim Moore with EF. Please proceed.
Tim Moore: Thanks. For new investors joining this call, maybe can you provide some anecdotes on how that’s fine, your testing kits exciting and useful in conveying that excitement K9 dog owners. Can you give any kind of interaction anecdotes or color behind that? It’s a rapid outcome test, but vets seem to be buying into the adoption of the early cancer detection and probably spreading the word. I mean any sense of that awareness for this rapid testing of cancer, you think like one-third of that’s know about it already?
Tom Butera: Yes. Thank you for the question. As I mentioned earlier in the call, early cancer detection is a new test and a new area of involvement for my veterinary colleagues. So we are obviously going around the world in terms of conferences where we’re speaking to both general practitioners as well as oncologists and also obviously spending a lot of time in the U.S. going to major meetings. So what we’re actually doing, there is robust interest in the cancer screening has, and they are learning from us as well as our partners on how to use the test and how to communicate it to the clients and how to bring it into their normal workload and normal examining patterns when they interact with their clients and their pet owners.
So consequently, the interest is significant. We’re spending a lot more time on how to use the test now and how to communicate it and then what to do after you get something that comes back normal. But — so you know the overall message with a screening test is one of piece of mines, close to 92% of the dollars that get — 92% of the dollars are going to come back in a normal range, and you have 6% to 8% potentially better in a higher range. But unfortunately, in the United States, we’re 6 million dogs a year level cancer, it’s a large number. So overall, the education continues with IDEXX, with our partners, with Heska and also with my own team, the Vet team here Volition, and that is an ongoing thing that we will continue to do throughout 2024 and 2025.
But the interest has been robust. The use is increasing dramatically, and we’re very excited about how our veterinary colleagues have received it.
Tim Moore: That’s great color. I appreciate it. My next question is about Heska in the milestone payments that possibly to be received over the next several months. Is it fair to just assume that with any companies that get taken over like the Mars takeover, that might have slowed down the milestone payment, but is it possible that Heska maybe launch both screening and monitoring at the same time that you can get a double milestone payment?
Tom Butera: Yes, I think that’s a great question. To answer the first part of the question with reference to the acquisition of Heska VMRs, that really, quite frankly, hasn’t slowed down the optimization process that we’ve been doing on the point of care. As I mentioned in my earlier comments, on the video that we have done today, we’re talking about a tech transfer going from a reference lab test to a point-of-care test, which is something that my veterinary colleagues use in their veterinary hospitals. It is a major accomplishment to do something like that. And consequently, it has taken some time to do it and it’s gone a little bit longer than we anticipated. But we’re almost there. And when you think about it from a 12-month period of time when this was started to where we are now, it’s a tremendous accomplishment where we’re getting very close to a launch. So that point is well taken and hopefully, understood.
Cameron Reynolds: [Multiple Speakers] screening.
Tom Butera: Yes. The good part about screening and monitoring. Since I’ve been in the field of Veterinary Medicine for a number of years. What you really want to do is you want to make sure that you’re getting your message across to the colleagues on not too many things at the same time. We want to be very clear on our Nu.Q cancer screening test, which is our first test and make sure they’re using it, using it effectively. And that is the direction we’re going in right now. And obviously, it’s out there and thousands of tests have been run at this point in time, and we’ll continue to do that. We will be entering the market with our monitoring application. We already have a peer-reviewed paper that came out in May of 2022. We are talking about it with our colleagues extensively, but we don’t want to mix confuse the message.
We anticipate that the monitoring application will probably really be introduced probably more like in the first quarter of 2024. And yes, to your point, will we get kind of a double with that between the screening and monitoring, of course, because both of those tests will interact with each other, and it will obviously bring even more credibility to both screening as well as monitoring. But we’re focused on the screening first, and now we’re continuing our education of the doctors on the monitoring, and that will follow suit after that.
Tim Moore: Great. That’s helpful. And my last question is just what do you think might be the time frame of the feline test launch? Is that more of December next year? And can you remind me when that does occur, does that trigger a $5 million milestone.
